Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2026-03-14 @ 6:35 PM
Study NCT ID:
NCT01428518
Status:
COMPLETED
Last Update Posted:
2016-04-25
First Post:
2011-09-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Special Drug Use Investigation for LAMICTAL Bipolar
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
Special Drug Use Investigation for LAMICTAL Bipolar
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This post-marketing surveillance study is designed to collect and assess information on safety and effectiveness of lamotrigine tablets in patients with bipolar disorder in routine clinical practice.
("LAMICTAL" is a trademark of the GlaxoSmithKline group of companies.)
("LAMICTAL" is a trademark of the GlaxoSmithKline group of companies.)
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: